Solid Tumors in RASopathies
Condition(s) studied
Investigational drug(s) / intervention(s)
Molecular characterization of solid tumor in RASopathies: NGS analysis on tumor sample
Study summary
RASopathies are a group of syndromes, caused by variants of genes involved in the regulation of the Ras/MAP/ERK pathway. This intracellular transduction pathway profoundly affects embryogenic development, organogenesis, synaptic plasticity and neuronal growth.
RASopathies are characterized by multi-organ involvement, growth delay, premature aging and haemato-oncological manifestations.
Based on evidences provided by literature, cancer screening protocols are applied in some individuals affected by RASopathies, even though detailed information about prevalence and molecular pathogenesis of such tumors is still not clearly elucidate.
Eligibility
Primary outcome measure(s)
- Prevalence of solid tumors in RASopathies — 5 years
To detect prevalence of solid tumors in monocentric cohort of RASopathies
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Department of Woman and Child Health and Public Health, Fondazione Policlinico A. Gemelli, IRCCS | Roma | Italy | Recruiting |
More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05761314 on ClinicalTrials.gov ↗ ← All trials in Italy